Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited .
Filed returns
32
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Novartis Ireland Limited | Health | National Cardiovascular Health Strategy (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Health System Readiness for Advanced Cancer Therapy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Attended an event for World Cancer Day (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) | 26 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Roundtable policy meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Implementation of the decision to include SMA in newborn screening (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invitation to a meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | American Chamber of Commerce Event (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | AI4Ireland meeting with Oireachtas members (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | World Urticaria Day event (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invited to the Joint Oireachtas All Party Committee on Orphan Drugs (3/12/25) (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Advocate for Life Science Strategy (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare Disease Ireland invite to Leinster House (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heel prick test (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Life Sciences strategy for Ireland (Public policy or programme) | 9 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | To fund an Office of Life Sciences or Life Science Strategy (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 25 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Access in Heart Failure (HF) & healthcare system readiness for new medicine platforms like radioligand therapies. Clinical trial attractiveness (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 6 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Ensure that the healthcare system is ready for new novel treatments like radioligand therapies. Also employing guideline-directed therapy for heart failure patients. (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Budget for innovative new medicines in 2024 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Expansion of newborn screening in Ireland (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | Novartis Ireland Limited | Health | Ensuring the spinal muscular atrophy (SMA) is added to the heel prick test in a timely manner (Matters involving public funds) | 11 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Expension of the newborn screening program - adding more diseases to the heel prick test (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2021 | Novartis Ireland Limited | Health | New born screening, timely access to new medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Novartis Ireland Limited | Health | Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) | 23 | On lobbying.ie |
| Sep–Dec 2016 | Novartis Ireland Limited | Health | Making Heart Failure a public policy priority (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2015 | Novartis Ireland Limited | Health | Highlighting the societal cost of multiple scelerosis (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2015 | Novartis Ireland Limited | Health | Making heart failure a national priority (Public policy or programme) | 19 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 32 | 100.0% |